Stem definition | Drug id | CAS RN |
---|---|---|
4191 | 286930-02-7 |
Dose | Unit | Route |
---|---|---|
4 | mg | O |
3.50 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 256 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.33 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 31, 2008 | FDA | PFIZER | |
April 20, 2007 | EMA | Pfizer Europe MA EEIG | |
Dec. 25, 2012 | PMDA | PFIZER JAPAN INC. |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urinary retention | 252.06 | 16.81 | 107 | 8054 | 30194 | 63450667 |
Dry mouth | 219.40 | 16.81 | 132 | 8029 | 77731 | 63403130 |
Brain injury | 105.00 | 16.81 | 38 | 8123 | 7005 | 63473856 |
Fall | 95.39 | 16.81 | 176 | 7985 | 392158 | 63088703 |
Pulseless electrical activity | 77.52 | 16.81 | 31 | 8130 | 7490 | 63473371 |
Urinary incontinence | 74.15 | 16.81 | 48 | 8113 | 31966 | 63448895 |
Multiple fractures | 73.44 | 16.81 | 31 | 8130 | 8587 | 63472274 |
Electrocardiogram QRS complex prolonged | 63.02 | 16.81 | 25 | 8136 | 5913 | 63474948 |
Catarrh | 54.40 | 16.81 | 16 | 8145 | 1533 | 63479328 |
Dysuria | 48.88 | 16.81 | 38 | 8123 | 33700 | 63447161 |
Steroid dependence | 48.12 | 16.81 | 15 | 8146 | 1749 | 63479112 |
Burns second degree | 46.43 | 16.81 | 15 | 8146 | 1963 | 63478898 |
Colitis ulcerative | 39.13 | 16.81 | 30 | 8131 | 26061 | 63454800 |
Hypopnoea | 36.85 | 16.81 | 15 | 8146 | 3791 | 63477070 |
Gait disturbance | 36.77 | 16.81 | 76 | 8085 | 183102 | 63297759 |
Frequent bowel movements | 35.69 | 16.81 | 27 | 8134 | 22995 | 63457866 |
Bradycardia | 34.90 | 16.81 | 45 | 8116 | 73182 | 63407679 |
Constipation | 34.69 | 16.81 | 84 | 8077 | 224859 | 63256002 |
Gingival pain | 34.23 | 16.81 | 18 | 8143 | 8144 | 63472717 |
Vertigo | 32.04 | 16.81 | 39 | 8122 | 59848 | 63421013 |
Nocturia | 28.70 | 16.81 | 16 | 8145 | 8125 | 63472736 |
Bladder spasm | 27.97 | 16.81 | 10 | 8151 | 1778 | 63479083 |
Tubulointerstitial nephritis | 27.92 | 16.81 | 22 | 8139 | 19881 | 63460980 |
Micturition urgency | 26.23 | 16.81 | 16 | 8145 | 9595 | 63471266 |
Dry throat | 25.78 | 16.81 | 14 | 8147 | 6751 | 63474110 |
Loss of consciousness | 24.85 | 16.81 | 50 | 8111 | 118071 | 63362790 |
Rectal haemorrhage | 24.73 | 16.81 | 31 | 8130 | 48999 | 63431862 |
Swollen tongue | 24.26 | 16.81 | 26 | 8135 | 34774 | 63446087 |
Parosmia | 24.09 | 16.81 | 13 | 8148 | 6193 | 63474668 |
Tinnitus | 23.76 | 16.81 | 26 | 8135 | 35602 | 63445259 |
Stress | 22.67 | 16.81 | 35 | 8126 | 67132 | 63413729 |
Rhinitis | 21.41 | 16.81 | 15 | 8146 | 11351 | 63469510 |
Impaired quality of life | 21.00 | 16.81 | 16 | 8145 | 13767 | 63467094 |
Product blister packaging issue | 20.77 | 16.81 | 5 | 8156 | 221 | 63480640 |
Therapeutic product effect incomplete | 20.65 | 16.81 | 48 | 8113 | 125008 | 63355853 |
Feeling abnormal | 20.31 | 16.81 | 53 | 8108 | 148339 | 63332522 |
Nightmare | 20.25 | 16.81 | 18 | 8143 | 19176 | 63461685 |
Cardiac murmur | 20.23 | 16.81 | 16 | 8145 | 14536 | 63466325 |
Overdose | 18.81 | 16.81 | 44 | 8117 | 115034 | 63365827 |
Bronchiectasis | 18.77 | 16.81 | 16 | 8145 | 16126 | 63464735 |
Anticholinergic syndrome | 18.41 | 16.81 | 8 | 8153 | 2374 | 63478487 |
Palpitations | 18.30 | 16.81 | 43 | 8118 | 112727 | 63368134 |
Pollakiuria | 17.95 | 16.81 | 20 | 8141 | 27917 | 63452944 |
Multiple sclerosis relapse | 17.40 | 16.81 | 26 | 8135 | 48452 | 63432409 |
Vision blurred | 17.09 | 16.81 | 37 | 8124 | 91887 | 63388974 |
Balance disorder | 16.87 | 16.81 | 35 | 8126 | 84387 | 63396474 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urinary retention | 415.46 | 21.92 | 149 | 3249 | 36139 | 34917394 |
Dry mouth | 106.63 | 21.92 | 54 | 3344 | 30111 | 34923422 |
Dysuria | 48.13 | 21.92 | 31 | 3367 | 27121 | 34926412 |
Fall | 41.37 | 21.92 | 72 | 3326 | 202813 | 34750720 |
Catarrh | 41.11 | 21.92 | 11 | 3387 | 991 | 34952542 |
Burns second degree | 39.81 | 21.92 | 11 | 3387 | 1118 | 34952415 |
Steroid dependence | 36.60 | 21.92 | 11 | 3387 | 1506 | 34952027 |
Hypertonic bladder | 34.37 | 21.92 | 11 | 3387 | 1853 | 34951680 |
Dementia | 32.82 | 21.92 | 19 | 3379 | 13729 | 34939804 |
Gingival pain | 32.72 | 21.92 | 12 | 3386 | 3040 | 34950493 |
Hypopnoea | 32.15 | 21.92 | 11 | 3387 | 2278 | 34951255 |
Parosmia | 31.53 | 21.92 | 11 | 3387 | 2414 | 34951119 |
Benign prostatic hyperplasia | 29.31 | 21.92 | 18 | 3380 | 14477 | 34939056 |
Cystitis interstitial | 29.22 | 21.92 | 6 | 3392 | 169 | 34953364 |
Systemic lupus erythematosus | 26.93 | 21.92 | 11 | 3387 | 3713 | 34949820 |
Swollen tongue | 26.66 | 21.92 | 17 | 3381 | 14588 | 34938945 |
Confusional state | 26.53 | 21.92 | 49 | 3349 | 144111 | 34809422 |
Vertigo | 22.19 | 21.92 | 19 | 3379 | 25517 | 34928016 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urinary retention | 308.05 | 16.71 | 146 | 9533 | 56484 | 79678225 |
Dry mouth | 191.35 | 16.71 | 124 | 9555 | 87895 | 79646814 |
Fall | 124.10 | 16.71 | 216 | 9463 | 487413 | 79247296 |
Brain injury | 88.97 | 16.71 | 38 | 9641 | 11479 | 79723230 |
Catarrh | 80.01 | 16.71 | 23 | 9656 | 2155 | 79732554 |
Multiple fractures | 77.29 | 16.71 | 31 | 9648 | 7995 | 79726714 |
Burns second degree | 71.48 | 16.71 | 22 | 9657 | 2606 | 79732103 |
Steroid dependence | 71.47 | 16.71 | 22 | 9657 | 2608 | 79732101 |
Pulseless electrical activity | 66.28 | 16.71 | 33 | 9646 | 14127 | 79720582 |
Urinary incontinence | 59.24 | 16.71 | 45 | 9634 | 40864 | 79693845 |
Gingival pain | 57.54 | 16.71 | 26 | 9653 | 8972 | 79725737 |
Hypopnoea | 56.26 | 16.71 | 22 | 9657 | 5307 | 79729402 |
Dysuria | 54.59 | 16.71 | 47 | 9632 | 50904 | 79683805 |
Parosmia | 50.42 | 16.71 | 22 | 9657 | 6992 | 79727717 |
Vertigo | 47.75 | 16.71 | 50 | 9629 | 69032 | 79665677 |
Electrocardiogram QRS complex prolonged | 47.05 | 16.71 | 24 | 9655 | 10809 | 79723900 |
Colitis ulcerative | 45.47 | 16.71 | 36 | 9643 | 34706 | 79700003 |
Frequent bowel movements | 43.88 | 16.71 | 33 | 9646 | 29506 | 79705203 |
Swollen tongue | 39.10 | 16.71 | 36 | 9643 | 42534 | 79692175 |
Gait disturbance | 38.97 | 16.71 | 81 | 9598 | 207425 | 79527284 |
Rectal haemorrhage | 37.06 | 16.71 | 46 | 9633 | 76254 | 79658455 |
Hypertonic bladder | 36.25 | 16.71 | 15 | 9664 | 4186 | 79730523 |
Cardiac murmur | 36.05 | 16.71 | 23 | 9656 | 15801 | 79718908 |
Impaired quality of life | 35.51 | 16.71 | 22 | 9657 | 14364 | 79720345 |
Rhinitis | 34.92 | 16.71 | 22 | 9657 | 14785 | 79719924 |
Nightmare | 30.04 | 16.71 | 25 | 9654 | 25836 | 79708873 |
Urinary tract infection | 29.01 | 16.71 | 86 | 9593 | 274426 | 79460283 |
Bronchiectasis | 28.87 | 16.71 | 23 | 9656 | 22363 | 79712346 |
Cystitis interstitial | 27.01 | 16.71 | 9 | 9670 | 1374 | 79733335 |
Tinnitus | 25.26 | 16.71 | 29 | 9650 | 44304 | 79690405 |
Stress | 25.12 | 16.71 | 39 | 9640 | 79573 | 79655136 |
Impaired work ability | 24.90 | 16.71 | 20 | 9659 | 19661 | 79715048 |
Dementia | 24.90 | 16.71 | 22 | 9657 | 24637 | 79710072 |
Benign prostatic hyperplasia | 24.29 | 16.71 | 16 | 9663 | 11596 | 79723113 |
Nocturia | 24.22 | 16.71 | 17 | 9662 | 13664 | 79721045 |
Therapeutic product effect incomplete | 23.93 | 16.71 | 53 | 9626 | 141592 | 79593117 |
Constipation | 23.81 | 16.71 | 82 | 9597 | 282968 | 79451741 |
Tubulointerstitial nephritis | 23.47 | 16.71 | 26 | 9653 | 38209 | 79696500 |
Confusional state | 23.25 | 16.71 | 88 | 9591 | 317909 | 79416800 |
Micturition urgency | 23.06 | 16.71 | 16 | 9663 | 12625 | 79722084 |
Bladder spasm | 22.38 | 16.71 | 9 | 9670 | 2334 | 79732375 |
Loss of consciousness | 22.07 | 16.71 | 57 | 9622 | 167886 | 79566823 |
Toxicity to various agents | 21.84 | 16.71 | 12 | 9667 | 421528 | 79313181 |
Accidental overdose | 21.06 | 16.71 | 25 | 9654 | 39556 | 79695153 |
Product blister packaging issue | 20.97 | 16.71 | 5 | 9674 | 225 | 79734484 |
Body height decreased | 20.87 | 16.71 | 13 | 9666 | 8567 | 79726142 |
Drug ineffective | 20.79 | 16.71 | 211 | 9468 | 1080702 | 78654007 |
Urine flow decreased | 20.72 | 16.71 | 7 | 9672 | 1114 | 79733595 |
Completed suicide | 19.98 | 16.71 | 3 | 9676 | 245764 | 79488945 |
Bradycardia | 19.90 | 16.71 | 48 | 9631 | 135509 | 79599200 |
Intentional product use issue | 19.34 | 16.71 | 51 | 9628 | 152061 | 79582648 |
Palpitations | 18.76 | 16.71 | 45 | 9634 | 126565 | 79608144 |
Cystitis | 18.29 | 16.71 | 27 | 9652 | 52705 | 79682004 |
Colitis ischaemic | 18.15 | 16.71 | 15 | 9664 | 15344 | 79719365 |
Bladder disorder | 17.66 | 16.71 | 12 | 9667 | 9153 | 79725556 |
Eczema | 17.28 | 16.71 | 23 | 9656 | 40795 | 79693914 |
Arthritis | 17.20 | 16.71 | 41 | 9638 | 114839 | 79619870 |
Product prescribing error | 17.08 | 16.71 | 24 | 9655 | 44789 | 79689920 |
Medication error | 16.79 | 16.71 | 30 | 9649 | 68612 | 79666097 |
None
Source | Code | Description |
---|---|---|
ATC | G04BD11 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs for urinary frequency and incontinence |
ATC | G04BD13 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs for urinary frequency and incontinence |
MeSH PA | D018678 | Cholinergic Agents |
MeSH PA | D018680 | Cholinergic Antagonists |
MeSH PA | D018727 | Muscarinic Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D064804 | Urological Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Urgent desire to urinate | indication | 75088002 | |
Urge incontinence of urine | indication | 87557004 | |
Bladder muscle dysfunction - overactive | indication | 236633002 | |
Increased Urinary Frequency | indication | ||
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Acute constipation | contraindication | 197119006 | |
Bladder outflow obstruction | contraindication | 236645006 | |
Retention of urine | contraindication | 267064002 | |
Gastric retention | contraindication | 307227006 | |
Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Gastrointestinal hypomotility | contraindication | 421807004 | |
Poor metabolizer due to cytochrome p450 CYP2D6 variant | contraindication | 423629005 | |
Aggravated Glaucoma | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.64 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
4MG | TOVIAZ | PFIZER | N022030 | Oct. 31, 2008 | RX | TABLET, EXTENDED RELEASE | ORAL | 7807715 | June 7, 2027 | TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY |
4MG | TOVIAZ | PFIZER | N022030 | Oct. 31, 2008 | RX | TABLET, EXTENDED RELEASE | ORAL | 8088398 | June 7, 2027 | TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY |
8MG | TOVIAZ | PFIZER | N022030 | Oct. 31, 2008 | RX | TABLET, EXTENDED RELEASE | ORAL | 7807715 | June 7, 2027 | TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY |
8MG | TOVIAZ | PFIZER | N022030 | Oct. 31, 2008 | RX | TABLET, EXTENDED RELEASE | ORAL | 8088398 | June 7, 2027 | TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
4MG | TOVIAZ | PFIZER | N022030 | Oct. 31, 2008 | RX | TABLET, EXTENDED RELEASE | ORAL | June 17, 2024 | TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING GREATER THAN 25 KG |
8MG | TOVIAZ | PFIZER | N022030 | Oct. 31, 2008 | RX | TABLET, EXTENDED RELEASE | ORAL | June 17, 2024 | TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING GREATER THAN 25 KG |
4MG | TOVIAZ | PFIZER | N022030 | Oct. 31, 2008 | RX | TABLET, EXTENDED RELEASE | ORAL | Dec. 17, 2024 | PEDIATRIC EXCLUSIVITY |
8MG | TOVIAZ | PFIZER | N022030 | Oct. 31, 2008 | RX | TABLET, EXTENDED RELEASE | ORAL | Dec. 17, 2024 | PEDIATRIC EXCLUSIVITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Muscarinic acetylcholine receptor M2 | GPCR | ANTAGONIST | Ki | 6.40 | WOMBAT-PK | CHEMBL | |||
Muscarinic acetylcholine receptor M3 | GPCR | ANTAGONIST | Ki | 6.27 | WOMBAT-PK | CHEMBL | |||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 6.39 | WOMBAT-PK | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 6.19 | WOMBAT-PK | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 5.98 | WOMBAT-PK |
ID | Source |
---|---|
4028101 | VUID |
N0000179802 | NUI |
D07226 | KEGG_DRUG |
286930-03-8 | SECONDARY_CAS_RN |
4028101 | VANDF |
4028102 | VANDF |
C2343853 | UMLSCUI |
CHEBI:135920 | CHEBI |
CHEMBL1201764 | ChEMBL_ID |
CHEMBL1201765 | ChEMBL_ID |
DB06702 | DRUGBANK_ID |
C526675 | MESH_SUPPLEMENTAL_RECORD_UI |
7473 | IUPHAR_LIGAND_ID |
8068 | INN_ID |
621G617227 | UNII |
6918558 | PUBCHEM_CID |
DB15578 | DRUGBANK_ID |
797195 | RXNORM |
137285 | MMSL |
25992 | MMSL |
358891 | MMSL |
d07162 | MMSL |
012671 | NDDF |
012672 | NDDF |
432254002 | SNOMEDCT_US |
432255001 | SNOMEDCT_US |
441469003 | SNOMEDCT_US |
C4301611 | UMLSCUI |
CHEMBL3348932 | ChEMBL_ID |
10020 | INN_ID |
207679-81-0 | SECONDARY_CAS_RN |
9819382 | PUBCHEM_CID |
YU871O78GR | UNII |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Toviaz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0242 | TABLET, FILM COATED, EXTENDED RELEASE | 4 mg | ORAL | NDA | 32 sections |
Toviaz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0242 | TABLET, FILM COATED, EXTENDED RELEASE | 4 mg | ORAL | NDA | 32 sections |
Toviaz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0242 | TABLET, FILM COATED, EXTENDED RELEASE | 4 mg | ORAL | NDA | 32 sections |
Toviaz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0244 | TABLET, FILM COATED, EXTENDED RELEASE | 8 mg | ORAL | NDA | 32 sections |
Toviaz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0244 | TABLET, FILM COATED, EXTENDED RELEASE | 8 mg | ORAL | NDA | 32 sections |
Toviaz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0244 | TABLET, FILM COATED, EXTENDED RELEASE | 8 mg | ORAL | NDA | 32 sections |
Fesoterodine fumarate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-247 | TABLET, EXTENDED RELEASE | 4 mg | ORAL | ANDA | 26 sections |
Fesoterodine fumarate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-248 | TABLET, EXTENDED RELEASE | 8 mg | ORAL | ANDA | 26 sections |
Fesoterodine Fumarate | Human Prescription Drug Label | 1 | 46708-175 | TABLET, EXTENDED RELEASE | 4 mg | ORAL | ANDA | 27 sections |
Fesoterodine Fumarate | Human Prescription Drug Label | 1 | 46708-176 | TABLET, EXTENDED RELEASE | 8 mg | ORAL | ANDA | 27 sections |
Fesoterodine fumarate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-661 | TABLET, EXTENDED RELEASE | 4 mg | ORAL | ANDA | 26 sections |
Fesoterodine fumarate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-662 | TABLET, EXTENDED RELEASE | 8 mg | ORAL | ANDA | 26 sections |
Toviaz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6156 | TABLET, FILM COATED, EXTENDED RELEASE | 4 mg | ORAL | NDA | 29 sections |
Toviaz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6175 | TABLET, FILM COATED, EXTENDED RELEASE | 8 mg | ORAL | NDA | 29 sections |
Fesoterodine Fumarate | Human Prescription Drug Label | 1 | 62332-175 | TABLET, EXTENDED RELEASE | 4 mg | ORAL | ANDA | 27 sections |
Fesoterodine Fumarate | Human Prescription Drug Label | 1 | 62332-176 | TABLET, EXTENDED RELEASE | 8 mg | ORAL | ANDA | 27 sections |
Fesoterodine Fumarate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-376 | TABLET, FILM COATED, EXTENDED RELEASE | 8 mg | ORAL | ANDA | 28 sections |
Toviaz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63539-183 | TABLET, FILM COATED, EXTENDED RELEASE | 8 mg | ORAL | NDA | 32 sections |
Toviaz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63539-183 | TABLET, FILM COATED, EXTENDED RELEASE | 8 mg | ORAL | NDA | 32 sections |
Toviaz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63539-242 | TABLET, FILM COATED, EXTENDED RELEASE | 4 mg | ORAL | NDA | 32 sections |
Toviaz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63539-242 | TABLET, FILM COATED, EXTENDED RELEASE | 4 mg | ORAL | NDA | 32 sections |
Fesoterodine Fumarate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-369 | TABLET, EXTENDED RELEASE | 4 mg | ORAL | ANDA | 20 sections |
Fesoterodine Fumarate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-370 | TABLET, EXTENDED RELEASE | 8 mg | ORAL | ANDA | 20 sections |
FESOTERODINE FUMARATE | Human Prescription Drug Label | 1 | 65862-766 | TABLET, FILM COATED, EXTENDED RELEASE | 4 mg | ORAL | ANDA | 27 sections |
FESOTERODINE FUMARATE | Human Prescription Drug Label | 1 | 65862-766 | TABLET, FILM COATED, EXTENDED RELEASE | 4 mg | ORAL | ANDA | 27 sections |
FESOTERODINE FUMARATE | Human Prescription Drug Label | 1 | 65862-767 | TABLET, FILM COATED, EXTENDED RELEASE | 8 mg | ORAL | ANDA | 27 sections |
FESOTERODINE FUMARATE | Human Prescription Drug Label | 1 | 65862-767 | TABLET, FILM COATED, EXTENDED RELEASE | 8 mg | ORAL | ANDA | 27 sections |
Fesoterodine Fumarate | Human Prescription Drug Label | 1 | 67877-064 | TABLET, EXTENDED RELEASE | 4 mg | ORAL | ANDA | 26 sections |
Fesoterodine Fumarate | Human Prescription Drug Label | 1 | 67877-068 | TABLET, EXTENDED RELEASE | 8 mg | ORAL | ANDA | 26 sections |
fesoterodine fumarate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-618 | TABLET, EXTENDED RELEASE | 4 mg | ORAL | ANDA | 27 sections |